Jonathan E Rosenberg
Overview
Explore the profile of Jonathan E Rosenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
251
Citations
15207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang N, Pachai M, Li D, Lee C, Warda S, Khudoynazarova M, et al.
Nat Genet
. 2025 Jan;
57(1):165-179.
PMID: 39806204
Members of the KMT2C/D-KDM6A complex are recurrently mutated in urothelial carcinoma and in histologically normal urothelium. Here, using genetically engineered mouse models, we demonstrate that Kmt2c/d knockout in the urothelium...
2.
Kim K, Alam S, Kuo F, Chen Z, Yip W, Katims A, et al.
Eur Urol
. 2024 Nov;
87(3):342-354.
PMID: 39550333
Background And Objective: Molecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed...
3.
Iyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400287.
PMID: 39499893
Purpose: Alterations in DNA damage response (DDR) genes, including , have been correlated with response to neoadjuvant cisplatin-based chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). The SWOG 1314...
4.
Sweis R, Gajate P, Morales-Barrera R, Lee J, Necchi A, De Braud F, et al.
JAMA Oncol
. 2024 Sep;
10(11):1565-1570.
PMID: 39298147
Importance: The oral pan-fibroblast growth factor receptor inhibitor rogaratinib previously demonstrated encouraging safety and efficacy in a phase 1 study of patients with urothelial cancer (UC) overexpressing messenger RNA (mRNA)....
5.
Apolo A, Ballman K, Sonpavde G, Berg S, Kim W, Parikh R, et al.
N Engl J Med
. 2024 Sep;
392(1):45-55.
PMID: 39282902
Background: Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical...
6.
Faiena I, Adhikary S, Schweitzer C, Astrow S, Grogan T, Funt S, et al.
J Immunother
. 2024 Aug;
47(9):351-360.
PMID: 39169899
Melanoma-associated antigen-A (MAGE-A) is expressed in multiple cancers with restricted expression in normal tissue. We sought to assess the MAGE-A3/A6 expression profile as well as immune landscape in urothelial (UC)...
7.
Chandran E, Iannantuono G, Atiq S, Akbulut D, Sinaii N, Simon N, et al.
BMJ Oncol
. 2024 Aug;
3(1).
PMID: 39086924
Background: Mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) occur in a subset of cancers and have been shown to confer sensitivity to immune checkpoint inhibition (ICI); however, there is...
8.
Moore A, Lobaugh S, Zhang Z, Rosenberg J, Iyer G, Teo M, et al.
Bladder Cancer
. 2024 Jul;
9(2):141-150.
PMID: 38993294
Background: Various radiotherapeutic regimens are used in the treatment of bladder cancer. Objective: We aimed to evaluate early toxicity and outcomes associated with hypofractionated radiation therapy (Hypo-RT), 55Gy in 20...
9.
Akbulut D, Whiting K, Teo M, Tallman J, Gokturk Ozcan G, Basar M, et al.
Mod Pathol
. 2024 Jul;
37(10):100557.
PMID: 38964503
Small cell carcinomas (SMC) of the lung are now molecularly classified based on the expression of transcriptional regulators (NEUROD1, ASCL1, POU2F3, and YAP1) and DLL3, which has emerged as an...
10.
Lenis A, Whiting K, Ravichandran V, Tallman J, Alam S, Chu C, et al.
JCO Precis Oncol
. 2024 May;
8:e2300274.
PMID: 38691813
Purpose: Patients with residual invasive bladder cancer after neoadjuvant chemotherapy (NAC) and radical cystectomy have a poor prognosis. Data on adjuvant therapy for these patients are conflicting. We sought to...